APM
CATX icon

Avidity Partners Management’s Perspective Therapeutics CATX Stock Holding History

Avidity Partners Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Buy
6,299,999
+250,000
+4% +$944K 3.44% 6
2026
Q1 		$25.2M Buy
6,049,999
+2,839,266
+88% +$12M 5.11% 4
2025
Q4 		$8.83M Buy
3,210,733
+216,700
+7% +$618K 2.55% 8
2025
Q3 		$10.3M Buy
2,994,033
+1,135,437
+61% +$4.14M 2.34% 10
2025
Q2 		$6.39M Sell
1,858,596
-338,674
-15% -$894K 1.27% 28
2025
Q1 		$4.68M Sell
2,197,270
-497,330
-18% -$1.49M 0.89% 42
2024
Q4 		$8.6M Sell
2,694,600
-749,402
-22% -$6.12M 0.84% 42
2024
Q3 		$46M Buy
3,444,002
+406,334
+13% +$5.4M 2.35% 11
2024
Q2 		$30.3M Buy
+3,037,668
New +$43.9M 1.29% 29

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Avidity Partners Management's CATX Position: Q2 2026 in Review

Avidity Partners Management increased its Perspective Therapeutics (CATX) stake by 4.1% in Q2 2026, buying an estimated $944K and bringing the position to 6,299,999 shares worth $21.5M. The position accounts for 3.44% of the portfolio, ranked #6.

Avidity Partners Management first reported a position in CATX in Q2 2024 and has held it in 9 quarters since. The position peaked at $46M in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Avidity Partners Management held 6,299,999 shares of Perspective Therapeutics worth $21.5M as of Q2 2026.
  • Avidity Partners Management bought 250,000 Perspective Therapeutics shares in Q2 2026, an estimated $944K.
  • Perspective Therapeutics made up 3.44% of Avidity Partners Management's portfolio in Q2 2026, its #6 holding.
  • Avidity Partners Management first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Avidity Partners Management's Perspective Therapeutics position peaked at $46M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.